Outcome

Innovator ETFs Publishes Latest Upside Cap Ranges for December Series of U.S. Equity Buffer ETFs™

Retrieved on: 
Wednesday, November 23, 2022
Lovell Minnick Partners, Milliman, AUM, OCC, Risk, ETF, Option, Funding, Government, Prospectus, Outcome, FLEX, Options Clearing Corporation, Emerging market, Fund, Sale, Structuring, Consultant, Investment, Security (finance), Life insurance, Bank, Risk management, Financial adviser

Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.

Key Points: 
  • Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.
  • As a result, the ETFs are not expected to move directly in line with the Reference Asset during the interim period.
  • Consequently, ETFs usually generate fewer capital gain distributions overall, which can make them somewhat more tax-efficient than mutual funds.
  • 5 Defined Outcome ETFs are not backed by the faith and credit of an Issuing institution, so they are not exposed to credit risk.

Maycomb Capital and ZOMA Foundation launch new fund to accelerate outcomes financing in Colorado

Retrieved on: 
Tuesday, November 15, 2022
Health, Executive, Environment, Organization, Partnership, Economic development, Workforce, Education, Multimedia, Outcome, Solution, Management, To Kill a Mockingbird

DENVER, Nov. 15, 2022 /PRNewswire/ -- Maycomb Capital and ZOMA Foundation today announced the launch of the Outcomes Finance Accelerator Fund. The $10 million fund is designed to provide risk-tolerant, outcomes-aligned financing to mission-driven organizations across a broad range of social and environmental sectors including education, environment, health, workforce and economic development.

Key Points: 
  • DENVER, Nov. 15, 2022 /PRNewswire/ -- Maycomb Capital and ZOMA Foundation today announced the launch of the Outcomes Finance Accelerator Fund.
  • Maycomb Capital leads the field in outcomes financing, a strategy for local governments and other stakeholders to fund what works and improve outcomes for under resourced communities.
  • Maycomb Capital's Outcomes Financing Funds: Maycomb Capital has over $80 million in flexible, impact-aligned capital focused on expanding access to economic opportunity using an outcomes-based approach.
  • This capital includes the Community Outcomes Fund and the Outcomes Finance Accelerator Fund .

Transaction Data Systems Adds Cardinal Health’s Outcomes Platform to Enable Greater Clinical Services

Retrieved on: 
Thursday, November 10, 2022
Data Management, Health, Technology, Software, General Health, Networks, Pharmaceutical, Pharmacist, TDS, NYSE, CAH, Technology, Population, Multimedia, IVR, Efficiency, Cardinal Health, Pharmacy, Solution, Virgin Islands, Workflow, Patient, CEO, Industry, Healthcare, Outcome

View the full release here: https://www.businesswire.com/news/home/20221110005249/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221110005249/en/
    Outcomes is a leader in connecting payer and pharmaceutical company medication adherence, quality and population health opportunities to pharmacists, said Jude Dieterman, CEO of Transaction Data Systems.
  • Through our best-in-class pharmacy management systems and integrating the Outcomes digital capabilities with our PrescribeWellness solution, we are excited to expand the reach of Outcomes, a leading provider of pharmacist-led clinical opportunities to our high-performing retail pharmacy network.
  • Together with the Outcomes platform, pharmacies using one of TDS pharmacy solutions will be able to seamlessly access opportunities to provide clinical care services for their patients, drive greater connectivity and streamline their workflow for greater operational efficiency.
  • The collaboration brings together TDS technology capabilities with Outcomes growing digital ecosystem, which connects pharmacies, payers and pharmaceutical companies.

Net Health's Research Team to Present Data on Key Findings at ACRM Conference

Retrieved on: 
Wednesday, November 9, 2022
Organization, Rehabilitation, Outcome, Brain, P.T, Patient, Compliance, DASH, Observational study, The Carlyle Group, EHR, Vertigo, American Congress of Rehabilitation Medicine, Algorithm, Physical medicine and rehabilitation, Efficiency, ACRM, COVID-19, United States Congress, Science, TR, PROMIS, View, Low back pain, Association, Health, Conference, Interest group, Caregiver, Dizziness, Measurement, Telerehabilitation, Multimedia, Adult, Validity, Technology, Pharmaceutical industry, Maintenance (technical), Risk management, Medical device, Online shopping, Research

PITTSBURGH, Nov. 9, 2022 /PRNewswire/ -- Highlighting the company's industry leadership, Net Health Research and Clinical Outcomes was selected to give three presentations at the 99th American Congress of Rehabilitation Medicine (ACRM) Conference, November 8 – 11 in Chicago.  ACRM is billed as the world's largest interdisciplinary rehabilitation research conference, bringing in top scientists and clinicians globally. 

Key Points: 
  • ACRM is billed as the world's largest interdisciplinary rehabilitation research conference, bringing in top scientists and clinicians globally.
  • Since its founding in 1992, FOTO has been involved in 139 research studies published in peer-reviewed medical or rehabilitation journals.
  • Wednesday, November 9 12:23 12:28 PM
    The presentations will be led by Daniel Deutscher, P.T., Ph.D., Senior Research Scientist for Net Health.
  • "We are excited and honored to have these three studies featured at ACRM," said Deanna Hayes, P.T., D.P.T., M.S., Director of Research and Clinical Outcomes for Net Health.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting

Retrieved on: 
Thursday, November 3, 2022
Adult, Survival, Hepatorenal syndrome, ACLF, Division, Partial-response maximum-likelihood, University, MNK, University of Pennsylvania, Institute of Liver and Biliary Sciences, Acute kidney injury, Hypoxia, DC, AASLD, Kidney, American Association for the Study of Liver Diseases, Boxed warning, Safety, Volume overload, FDA, Association, Risk, Time, Oxygen saturation (medicine), HRS, Research, American Association, Efficacy, Terlipressin, NYSE, Mortality, Renal replacement therapy, 2021 Essex County Council election, Use, Health, Kidney failure, Completeness, ICA, Outcome, International Club Crosby, Pharmaceutical industry, Medical device, Poultry, Medicine, Gastroenterology, Patient, Mallinckrodt, Criterion, Hepatology

DUBLIN, Nov. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that seven scientific abstracts on clinical and health economic outcomes research on treatment with TERLIVAZ® (terlipressin) for adult patients with hepatorenal syndrome (HRS) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization2 will be presented at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting in Washington, DC, from November 4-8. TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS).1 

Key Points: 
  • Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk.
  • Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO2 decreases below 90%.
  • Serious or Fatal Respiratory Failure: Obtain baseline oxygen saturation and do not initiate TERLIVAZ in hypoxic patients.
  • For patients with high prioritization for liver transplantation (e.g., MELD 35), the benefits of TERLIVAZ may not outweigh its risks.

Innovator ETFs Announces Latest Upside Caps for November Series of U.S. Equity Buffer ETFs™

Retrieved on: 
Tuesday, November 1, 2022
Consultant, Milliman, ETF, LLC, Prospectus, Risk, COVID-19, Option, Structuring, Lovell Minnick Partners, Government, Sale, Emerging market, Investment, Funding, FLEX, Options Clearing Corporation, Outcome, Fund, OCC, AUM, Security (finance), Life insurance, Bank, Risk management, Financial adviser

Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.

Key Points: 
  • Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.
  • The outbreak of COVID-19 has negatively affected the worldwide economy, individual countries, individual companies and the market in general.
  • Consequently, ETFs usually generate fewer capital gain distributions overall, which can make them somewhat more tax-efficient than mutual funds.
  • 5 Defined Outcome ETFs are not backed by the faith and credit of an Issuing institution, so they are not exposed to credit risk.

Innovator ETFs Announces Latest Upside Cap Ranges for November Series of U.S. Equity Buffer ETFs™

Retrieved on: 
Tuesday, October 25, 2022
Emerging market, LLC, Prospectus, FLEX, Options Clearing Corporation, Sale, Option, Structuring, COVID-19, AUM, Investment, Lovell Minnick Partners, Government, Fund, ETF, Funding, Outcome, Risk, Milliman, OCC, Consultant, Security (finance), Life insurance, Bank, Risk management, Financial adviser

Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.

Key Points: 
  • Unlike structured notes, which offer limited liquidity, Innovator Defined Outcome ETFs trade throughout the day on an exchange, like a stock.
  • The outbreak of COVID-19 has negatively affected the worldwide economy, individual countries, individual companies and the market in general.
  • Consequently, ETFs usually generate fewer capital gain distributions overall, which can make them somewhat more tax-efficient than mutual funds.
  • 5 Defined Outcome ETFs are not backed by the faith and credit of an Issuing institution, so they are not exposed to credit risk.

DeepIntent Unveils the Fastest Omnichannel Campaign Measurement Tool with Near-Real Time Script Lift at Digital Pharma East

Retrieved on: 
Monday, October 17, 2022
Adoption, LinkedIn, Memorial Sloan Kettering Cancer Center, Data science, Comparison of multi-paradigm programming languages, DSP, Patient, Twitter, Technology, SVP, United States Unified Medical Command, Industry, Marketplace, Health, Atrium Health Union, CEO, Social media, Patent, Advertising, HCP, Pharmacy, Solution, Pharmaceutical industry, Public relations, Medicx Fund, Facebook, Outcome

NEW YORK, Oct. 17, 2022 /PRNewswire/ -- DeepIntent, the leading healthcare advertising technology company built to improve patient health and business outcomes, now offers pharmaceutical advertisers the ability to measure the real-world effectiveness of their entire media plan with the industry's fastest omnichannel measurement solution based on clinical data.

Key Points: 
  • "When we launched DeepIntent Outcomes, we set out to change how pharma uses campaign measurement.
  • "I am confident that, with this new release, DeepIntent has established the new standard for pharmaceutical campaign measurement."
  • In addition to Outcomes' new measurement solutions, DeepIntent will be showcasing its recently-launched Patient Planner at this year's Digital Pharma East conference in Philadelphia.
  • These new, innovative products being showcased at Digital Pharma East continue the momentum behind DeepIntent's continued investment in tools that improve campaign planning, activation, measurement, and optimization.

ERI Receives Overall “A” Rating from Ellen MacArthur Foundation’s Circular Economy Performance Measurement Tool

Retrieved on: 
Tuesday, October 11, 2022
Environment, Technology, Security, Sustainability, Green Technology, Internet, Hardware, Data Management, Recycling, Consumer Electronics, MacArthur Foundation, Electronics, Network, SOC, ESG, Organization, Foundation, Privacy, ERI, Recycling, Enablers, Ellen MacArthur Foundation, Certification, Goal, Industry, SOC 2, MacArthur, Nature, Electronic waste, Climate change, Environment, DNA, Ellen, Outcome, Solution, Management

ERI , the nations largest fully integrated IT and electronics asset disposition (ITAD) provider and cybersecurity-focused hardware destruction company, announced today that it has achieved an overall A rating from the Ellen MacArthur Foundations circular economy performance tool Circulytics.

Key Points: 
  • ERI , the nations largest fully integrated IT and electronics asset disposition (ITAD) provider and cybersecurity-focused hardware destruction company, announced today that it has achieved an overall A rating from the Ellen MacArthur Foundations circular economy performance tool Circulytics.
  • Fundamentally, the tool helps companies transition to a circular was of doing business, versus conventional linear business models.
  • ERI received an A score across all themes in the Enablers category and an A- score in the Outcomes category, with an overall score of A.
  • We are proud to have achieved a solid A grade overall and look to continue building upon this success.

Apixio Earns 2022 Technology Innovation Leadership Award from Frost & Sullivan for Healthcare Data Unification Platform that Advances Value-based Care

Retrieved on: 
Tuesday, September 27, 2022
Adoption, Gaps, Risk, Industry, Creativity, Acquisition, Outcome, Technology, Frost & Sullivan, Solution, Frost, AI, Medical device

SAN MATEO, Calif., Sept. 27, 2022 /PRNewswire/ -- Apixio, a leading AI platform that powers value-based care, today announced that its healthcare data unification platform earned the prestigious Frost & Sullivan 2022 Technology Innovation Leadership Award. The award recognizes Apixio's unique ability to unify healthcare data, leveraging AI and advanced technology to deliver actionable insights to healthcare organizations that can improve patient outcomes and support the delivery of value-based care.

Key Points: 
  • Apixio's AI-driven Platform Recognized for Addressing Industry Gaps, LeveragingTechnology to Improve Healthcare Access, Affordability, and Outcomes
    SAN MATEO, Calif., Sept. 27, 2022 /PRNewswire/ -- Apixio , a leading AI platform that powers value-based care, today announced that its healthcare data unification platform earned the prestigious Frost & Sullivan 2022 Technology Innovation Leadership Award.
  • According to Frost & Sullivan's overview report , the 2022 Technology Innovation Leadership Awardrecognized Apixio as "the company that has introduced the best underlying technology for achieving remarkable product and customer success while driving future business value."
  • After assessing Apixio and other nominees in the North American healthcare data unification marketplace, Frost & Sullivan named Apixio the 2022 Technology Innovation Leadership Award recipient.
  • We are proud that Frost & Sullivan has recognized the differentiated impact of our platform and named Apixio as the 2022 Technology Innovation Leader."